Fatty liver new treatment found: Study discovers a medicine that reverses severe fatty liver by just repairing the gut

A new experimental drug has shown it can heal severe fatty liver disease in animals, not by attacking the liver directly, but by fixing a damaged gut first. Scientists say the discovery could open a fresh treatment path for a disease that has no approved cure and is silently spreading among urban population.

For years, doctors have struggled to find an effective medicine for one of the most stubborn liver conditions around, metabolic dysfunction-associated steatohepatitis, or MASH. It’s the advanced, dangerous cousin of the “fatty liver” diagnosis that shows up on countless ultrasound reports across Indian cities today. Left untreated, it can quietly progress to cirrhosis, liver cancer, and complete liver failure.

Also Read: Why people sleep with phones next to bed? Psychology and sociology studies say it’s not because of any addiction or love for gadgets

Now, researchers at Michigan Medicine, part of the University of Michigan, believe they may have found a way to stop, and even reverse, the disease. Their weapon isn’t aimed at the liver at all. It’s aimed at the gut.

The Gut-Liver Connection Nobody Talked About

The study, published in The Journal of Clinical Investigation, centres on an experimental compound called DT-109, a small molecule built from three amino acids (scientifically termed a tripeptide). Earlier research from the same lab had already hinted that DT-109 could ease fatty liver disease in animals. This new study finally explains why it works, and the answer surprised even the scientists.

The team discovered that MASH doesn’t start and end in the liver. It often begins with an overgrowth of a gut bacterium called Clostridium perfringens, which floods the intestines with ammonia. That ammonia slowly eats away at the lining of the gut, weakening its natural barrier. Once that barrier breaks down, toxins and bacterial byproducts leak into the bloodstream, travel straight to the liver, and trigger an inflammatory attack, including an overactive immune response involving cells known as CD8+ T cells.

In short: a damaged gut can quietly poison the liver.

DT-109 appears to interrupt this chain reaction. In tests on both mice and, more importantly, non-human primates, whose gut and liver biology closely mirrors that of humans, the drug cut down harmful bacterial overgrowth, lowered ammonia levels, and helped the intestinal wall repair itself. With the gut barrier restored, far fewer toxins reached the liver, and inflammation eased significantly. In the primate trials, this translated into a marked improvement in the severity of MASH itself.According to the study’s senior author, the compound gives the gut lining real protection, cutting down the flow of harmful bacterial substances long believed to fuel the onset and worsening of MASH. Researchers also noted that although DT-109 mainly works inside the digestive tract, its protective effect appears to travel far beyond it.

Why This Matters

Fatty liver disease is no longer a rare finding in hospitals, it has quietly become one of the country’s biggest emerging health concerns. Multiple Indian studies over the past decade have estimated that roughly one in three adults in the country may have some degree of fatty liver disease, with numbers climbing even higher among people who are overweight, diabetic, or lead sedentary, desk-bound lives, a pattern increasingly common in India’s IT and urban office workforce. Rising obesity, sugar-heavy diets, and inactivity have all been blamed for the surge.

Also Read: 101-year-old working woman, who lives alone in New York, shares 3 tips to live longer, healthier, and happier, and none is about fitness

A meaningful share of these cases can silently progress to the more dangerous MASH stage without any obvious symptoms, often being detected only when the liver is already significantly damaged. Because there is currently no widely approved drug that reliably reverses this condition, most doctors are limited to advising weight loss, dietary changes, and exercise, advice that is hard for many patients to sustain long-term.

This is exactly why researchers are calling the DT-109 findings significant. A leading hepatologist involved with the research pointed out that the study offers real insight into how MASH develops, and gives fresh hope for a therapy that is both effective and safe, something patients with this condition have been waiting for.

Beyond the Liver: A Possible Two-in-One Treatment

Interestingly, DT-109 may not stop at liver disease. Earlier animal studies had already shown that the compound could shrink artery-clogging plaques and prevent calcium buildup in blood vessels, pointing to a possible role in preventing heart disease as well, a major bonus, since fatty liver disease and cardiovascular disease frequently occur together in the same patients. Scientists also believe the drug’s gut-repairing properties could eventually be tested for other conditions linked to a weakened intestinal lining, such as inflammatory bowel disease.

The Reality Check: Still Early Days

Before anyone gets ahead of themselves, it’s worth underlining that these results come from laboratory and animal studies, not from human patients. The compound, developed with support from Diapin Therapeutics, will now need to go through the rigorous phases of human clinical trials to confirm that it is both safe and effective in people. That process typically takes several years.

Still, for a disease that affects hundreds of millions of people worldwide and has no dedicated cure, a treatment strategy that targets the gut instead of the liver marks a genuinely new direction, and one doctors and patients alike will be watching closely in the years ahead.

(Disclaimer: This article is based on findings from an animal-model study published in a peer-reviewed journal. The treatment discussed is experimental and has not yet been approved for human use. Readers with concerns about liver health should consult a qualified doctor for diagnosis and treatment.)